Jatenzo Cost in Alaska 2026: Cash Price, Insurance, and Compounded Alternatives

What Is Jatenzo and Why Does It Cost So Much?

Jatenzo is the first FDA-approved oral testosterone replacement therapy for adult men with hypogonadism caused by a confirmed medical condition. The drug uses a self-emulsifying drug delivery system that bypasses first-pass hepatic metabolism via lymphatic absorption, which is why it behaves differently from older oral androgens. Swerdloff et al. (2020) confirmed in a 120-day, open-label Phase 3 study (N=166) that 87.8% of men achieved average total testosterone concentrations within the normal range (300, 1 to 050 ng/dL) on Jatenzo, with a geometric mean T of 489 ng/dL at the 237 mg dose. [1]

Brand-only status drives the cost. Tolmar Pharmaceuticals holds the exclusive NDA (NDA 210654) approved March 27, 2019. [2] No FDA-approved generic oral testosterone undecanoate capsule exists in 2026. Without generic competition, the manufacturer sets list price at roughly $900 per month and retail pharmacies in Alaska reflect that list price almost exactly. Rural Alaska adds a small dispensing-fee premium at independent pharmacies because of supply-chain logistics, though mail-order and specialty pharmacies that ship to Alaska often match the $900 figure.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act, which prevents standard pharmaceutical wholesale discounting channels from functioning the way they do for non-controlled drugs. That constraint also limits which pharmacy benefit managers will actively negotiate the price down. The net result: cash-paying Alaskans face the full $900 list price at the counter unless they use one of the programs described below.

Dose titration can also affect monthly cost. The prescribing label allows starting at 237 mg twice daily, then adjusting to 158 mg or 396 mg twice daily based on a serum testosterone drawn 3 to 5 hours post-dose. [2] Patients who titrate to 396 mg twice daily receive the same number of capsules per fill but at a higher labeled dose, so the per-fill cost stays near $900 regardless of the dose step selected.

Alaska Medicaid Coverage for Jatenzo

Alaska Medicaid does not cover Jatenzo as of 2026. This is consistent with a broader national pattern: fewer than half of state Medicaid programs list testosterone undecanoate oral capsules on their preferred drug lists, and Alaska's Division of Health Care Services has not added the drug to the Alaska Medicaid fee-for-service formulary. [3]

Men enrolled in Denali KidCare or adult Medicaid managed care plans administered through Alaska Native Tribal Health Consortium (ANTHC) channels should confirm with their specific plan, because formulary decisions for tribal compact plans can differ from fee-for-service Medicaid. The short answer remains: do not assume coverage without calling the plan directly.

For patients whose only payer is Alaska Medicaid, the practical path is either a formulary exception request (rarely successful for a brand-only drug without a generic equivalent) or a clinical appeal documenting that alternatives such as injectable testosterone cypionate or testosterone enanthate are contraindicated or not tolerated. The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism notes that the choice of testosterone formulation should be individualized to the patient based on pharmacokinetics, side-effect profile, and patient preference. [4] That language can support an appeal, though approval is not guaranteed.

Injectable testosterone cypionate (200 mg/mL vials) is covered by Alaska Medicaid and costs roughly $30, $60 per month at Medicaid rates. For patients who cannot tolerate injections and cannot afford Jatenzo out of pocket, 503A-compounded oral testosterone undecanoate is the next option (see the section below).

Private Insurance Coverage in Alaska

Private commercial plans in Alaska, including Premera Blue Cross, Moda Health, and federal employee FEHB plans, may cover Jatenzo, but prior authorization (PA) is almost always required. PA criteria typically include:

• A documented serum total testosterone below 300 ng/dL on two separate morning draws. [4]
• A confirmed etiology (primary or secondary hypogonadism, not age-related decline alone).
• A trial or documented contraindication to at least one lower-cost testosterone formulation (usually injectable testosterone cypionate or a generic topical gel).
• A prescribing physician's attestation that Jatenzo is medically necessary for this specific patient.

After successful PA, most commercial plans place Jatenzo on tier 3 or tier 4, producing a patient copay between $60 and $200 per month depending on plan design. High-deductible health plan (HDHP) members pay the full negotiated rate, often $600, $800 per month, until the deductible is met.

The FDA label for Jatenzo (NDA 210654) states that Jatenzo is indicated for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. [2] Framing the PA letter around that specific language, and citing the Swerdloff 2020 Phase 3 data showing 87.8% of patients achieving normal-range testosterone, strengthens the submission. [1]

If a PA is denied, Tolmar's internal appeals support team can provide letter templates. The HealthRX clinical team has seen commercially insured Alaskan patients achieve tier-3 coverage after a single appeal in a median of 18 days, though this figure is based on internal case review rather than published trial data.

Tolmar Savings Card: How It Works in Alaska

Tolmar offers a manufacturer savings card for Jatenzo. Eligible commercially insured patients may pay as little as $0 for their first prescription fill and a reduced copay thereafter, subject to a monthly cap and annual maximum benefit. Cash-paying patients without any insurance may also qualify for a separate cash-pay assistance tier.

Key program details (verify current terms at tolmar.com or via the HealthRX patient services line before enrolling):

• Eligibility: commercially insured patients in the United States, including Alaska. Medicare, Medicaid, and other federal program beneficiaries are not eligible, consistent with federal anti-kickback statute requirements. [5]
• Monthly savings cap: up to $200 off the patient copay per fill, with a typical annual maximum of $2 to 400 in total savings.
• Enrollment: online or by phone; the pharmacist applies the card at the point of sale.
• Pharmacy network: most major retail chains and mail-order pharmacies that stock Schedule III controlled substances. In rural Alaska, confirm your local pharmacy participates before relying on the card.

The savings card does not help Medicaid patients or Medicare Part D enrollees. For those groups, the 503A compounding route or the Tolmar Patient Assistance Program (PAP), which provides free drug to qualifying low-income patients, may be the only affordable paths. PAP eligibility typically requires income at or below 400% of the federal poverty level and proof that no other coverage is available.

503A Compounded Oral Testosterone Undecanoate in Alaska

Compounded oral testosterone undecanoate prepared by a 503A-licensed compounding pharmacy is legal in Alaska in 2026. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. [6] Compounded products are not FDA-approved and are not subject to FDA's new drug approval process, but 503A pharmacies operate under state board of pharmacy oversight and must comply with USP Chapter 795 standards for non-sterile compounding.

Cost is the headline advantage. Compounded oral testosterone undecanoate capsules typically run $60, $150 per month at specialty compounding pharmacies that ship to Alaska, compared to $900 for brand Jatenzo. Some 503A pharmacies working within integrated telehealth models charge as little as $0 for the medication when bundled with a subscription-based care model.

The clinical trade-off is real. Compounded oral testosterone undecanoate has not been evaluated in FDA-reviewed clinical trials. The bioavailability and pharmacokinetic profile may differ from Jatenzo's proprietary self-emulsifying capsule formulation. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism found that Jatenzo's lymphatic absorption mechanism produced stable dihydrotestosterone (DHT) and total testosterone levels with twice-daily dosing when taken with fatty meals. [1] Whether a compounded capsule from a given 503A pharmacy replicates that pharmacokinetic curve depends entirely on that pharmacy's excipient formulation and quality controls.

Patients switching from Jatenzo to a compounded product should have serum total testosterone rechecked 4 to 6 weeks after the switch, drawn 3 to 5 hours post-dose to match the Jatenzo monitoring protocol described in the FDA label. [2] A level below 300 ng/dL or above 1 to 050 ng/dL warrants a dose adjustment or formulation reconsideration.

Alaska does not have 503B outsourcing facilities licensed specifically for testosterone undecanoate oral capsules as of early 2026, so patients must use a 503A pharmacy operating under an individual patient prescription. The FDA guidance on compounding under Section 503A clarifies that 503A pharmacies may compound drugs that are commercially available provided the compounded version is not essentially a copy, which remains a legally gray area for testosterone undecanoate given Jatenzo's brand-only status. [6] Patients should confirm their prescriber and pharmacy are comfortable with this regulatory context before proceeding.

Telehealth Prescribing of Jatenzo in Alaska

Telehealth prescribing of Jatenzo is permitted in Alaska in 2026. Alaska joined most other states in maintaining pandemic-era telehealth flexibilities through state legislation, allowing controlled substances including Schedule III testosterone to be prescribed via audio-video telemedicine encounters without a prior in-person visit, subject to DEA telehealth prescribing rules. [7]

The DEA's Telemedicine Prescribing Rule, finalized in stages beginning in 2023, requires that a practitioner conducting a telemedicine encounter for a Schedule III controlled substance must hold a valid DEA registration in the state where the patient is located. Alaska is its own DEA registration jurisdiction. HealthRX prescribers hold Alaska DEA registrations and can evaluate, diagnose, and prescribe Jatenzo or compounded oral testosterone for Alaska residents via a compliant audio-video visit.

A telehealth visit for testosterone evaluation should include a review of two morning serum testosterone lab results (drawn on separate days, before 10 a.m.), a thorough symptom assessment using a validated tool such as the Androgen Deficiency in Aging Males (ADAM) questionnaire, and a discussion of cardiovascular risk factors given Jatenzo's label warning about blood pressure elevation. [2] [8] In the Swerdloff 2020 Phase 3 trial, systolic blood pressure increased by a mean of 3 to 4 mmHg during the 120-day treatment period, which was statistically significant at P<0.01 compared to baseline. [1]

Rural Alaskans in villages accessible only by bush plane or ferry have particular reason to pursue telehealth: travel to an endocrinologist in Anchorage or Fairbanks can cost more than the drug itself when factoring in flights and lodging. Telehealth eliminates that barrier for routine follow-up, though the initial lab draw still requires a local clinic or a mobile lab draw service.

How Jatenzo Is Dosed and Why Dosing Affects Cost

The FDA-approved dosing schedule is twice daily with a meal containing at least 19 grams of fat. The starting dose is 237 mg twice daily. After the first titration check (serum testosterone drawn 3 to 5 hours after the morning dose, between day 35 and day 90 of therapy), the prescriber adjusts to 158 mg twice daily if testosterone is above 1 to 050 ng/dL, maintains 237 mg if in range, or increases to 396 mg twice daily if below 300 ng/dL. [2]

All three dose levels are dispensed as the same SKU. Cost per month does not change with dose step because the number of capsules dispensed per fill is the same across dose levels (the individual capsule strengths differ, but the 30-day supply count is identical). That means an Alaska patient paying $900 cash pays $900 whether they take 158 mg or 396 mg twice daily.

The fat requirement is not trivial. A meal of at least 19 grams of fat is roughly equivalent to two eggs fried in butter, or a standard fast-food breakfast sandwich. Patients who take Jatenzo in a fasted state or with a very low-fat meal may see significantly reduced testosterone absorption. The Endocrine Society guideline recommends patient counseling on meal fat content as part of testosterone therapy initiation. [4] Pharmacists in Alaska dispensing Jatenzo should include this counseling at every new fill.

Blood Pressure Monitoring: A Required Part of Jatenzo Therapy

The Jatenzo FDA label carries a boxed warning about blood pressure increase. [2] The label requires blood pressure measurement before starting therapy and during therapy. Men with a baseline systolic blood pressure above 140 mmHg or diastolic above 90 mmHg need cardiovascular risk optimization before initiating Jatenzo. [9]

In Swerdloff et al. (2020), mean systolic blood pressure rose 3.5 mmHg and mean diastolic rose 2.0 mmHg over 120 days. [1] These are average figures; individual patients showed increases of 10 mmHg or more. The American Heart Association's 2017 Hypertension Guideline classifies systolic blood pressure of 130 to 139 mmHg as stage 1 hypertension, meaning even a modest Jatenzo-induced rise can push a borderline patient into a higher-risk category. [9]

Alaska Medicaid covers standard blood pressure monitoring visits, so Medicaid patients who are pursuing off-formulary Jatenzo through other funding sources can still get monitoring covered. Commercial insurance covers blood pressure checks as preventive care under the ACA. Telehealth patients should own a validated home blood pressure cuff and report readings at each follow-up encounter.

Comparing Jatenzo to Alternatives Available in Alaska

Several other testosterone formulations are available in Alaska with lower out-of-pocket costs for most patients:

Injectable testosterone cypionate or enanthate (generic): $30, $60 per month at most Alaska pharmacies. Covered by Alaska Medicaid. Requires intramuscular injection every 1 to 2 weeks (cypionate) or every 1 to 4 weeks (enanthate). Produces supraphysiologic peaks and lower troughs versus Jatenzo's twice-daily oral dosing. [4]

Testosterone gel (generic 1% or 1.62%): $40, $120 per month generic. Covered by most Alaska commercial plans at tier 2. Requires daily application and avoidance of skin-to-skin transfer to women and children. [2]

Testosterone pellets (Testopel): Implanted subcutaneously every 3 to 6 months. Cost varies widely ($500, $1,500 per implant procedure in Alaska). Insurance coverage is inconsistent.

Compounded oral testosterone undecanoate (503A): $60, $150 per month from specialty pharmacies shipping to Alaska. Not FDA-approved.

Jatenzo: $900 per month cash. The only FDA-approved oral option. Preferred for patients who refuse injections and need twice-daily oral dosing without the skin-transfer concerns of gels.

The right choice depends on patient anatomy, lifestyle, cardiovascular status, and payer. A 230-pound Alaska commercial fisherman who works 12-hour shifts may prefer oral twice-daily dosing over injections. A retired Anchorage teacher on fixed income with Alaska Medicaid will be directed to injectable testosterone cypionate almost automatically.

Steps to Get Jatenzo at the Lowest Cost in Alaska

Use this sequence:

1. Confirm hypogonadism diagnosis with two morning testosterone labs below 300 ng/dL drawn on separate days before 10 a.m. [4]
2. Complete a telehealth visit with a DEA-registered Alaska prescriber (in-person or audio-video).
3. Ask the prescriber to submit a prior authorization to your commercial insurer before sending the prescription to the pharmacy.
4. If insured commercially, enroll in the Tolmar savings card at time of first fill. Bring the card number to the pharmacy.
5. If PA is denied, request a peer-to-peer review between your prescriber and the insurer's medical director, citing Swerdloff 2020 efficacy data [1] and the Endocrine Society guideline individualization language. [4]
6. If on Medicaid or uninsured and the Tolmar PAP income criteria are met, apply directly through Tolmar before filling.
7. If none of the above brings cost to an acceptable level, ask your prescriber for a 503A compounded oral testosterone undecanoate prescription and select a specialty compounding pharmacy that ships to Alaska.
8. Recheck serum testosterone 4 to 6 weeks after starting any formulation, and monitor blood pressure at 4 weeks and 3 months. [2]